This HTML5 document contains 117 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01399/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01399/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01399/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01399/identifier/drugbank/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://www.rxlist.com/cgi/generic/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01399/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n23http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01399/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01399
rdf:type
n3:Drug
n3:description
Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
n3:group
approved
n3:halfLife
The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
n3:indication
For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.
owl:sameAs
n20:DB01399 n24:DB01399
dcterms:title
Salsalate
adms:identifier
n8:PA164745462 n15:DB01399 n16:D00428 n17:4977 n18:46506882 n21:5161
n3:mechanismOfAction
The mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined, but appears to be primarily associated with inhibition of prostaglandin synthesis. This inhibition of prostaglandin synthesis is done through the inactivation of cyclooxygenase-1 (COX-1) and COX-2, which are reponsible for catalyzing the formation of prostaglandins in the arachidonic acid pathway. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo, providing anti-inflammatory activity equivalent to aspirin and indomethacin. Unlike aspirin, salsalate does not inhibit platelet aggregation.
n3:packager
n4:271B460E-363D-11E5-9242-09173F13E4C5 n4:271B460F-363D-11E5-9242-09173F13E4C5 n4:271B460C-363D-11E5-9242-09173F13E4C5 n4:271B460D-363D-11E5-9242-09173F13E4C5 n4:271B4607-363D-11E5-9242-09173F13E4C5 n4:271B4608-363D-11E5-9242-09173F13E4C5 n4:271B4605-363D-11E5-9242-09173F13E4C5 n4:271B4606-363D-11E5-9242-09173F13E4C5 n4:271B4601-363D-11E5-9242-09173F13E4C5 n4:271B4604-363D-11E5-9242-09173F13E4C5 n4:271B45FF-363D-11E5-9242-09173F13E4C5 n4:271B4600-363D-11E5-9242-09173F13E4C5 n4:271B45FD-363D-11E5-9242-09173F13E4C5 n4:271B45FE-363D-11E5-9242-09173F13E4C5 n4:271B460B-363D-11E5-9242-09173F13E4C5 n4:271B4609-363D-11E5-9242-09173F13E4C5 n4:271B460A-363D-11E5-9242-09173F13E4C5 n4:271B4602-363D-11E5-9242-09173F13E4C5 n4:271B4603-363D-11E5-9242-09173F13E4C5 n4:271B45FB-363D-11E5-9242-09173F13E4C5 n4:271B45FC-363D-11E5-9242-09173F13E4C5 n4:271B4625-363D-11E5-9242-09173F13E4C5 n4:271B4626-363D-11E5-9242-09173F13E4C5 n4:271B4623-363D-11E5-9242-09173F13E4C5 n4:271B4624-363D-11E5-9242-09173F13E4C5 n4:271B4621-363D-11E5-9242-09173F13E4C5 n4:271B4622-363D-11E5-9242-09173F13E4C5 n4:271B461F-363D-11E5-9242-09173F13E4C5 n4:271B4620-363D-11E5-9242-09173F13E4C5 n4:271B461D-363D-11E5-9242-09173F13E4C5 n4:271B461E-363D-11E5-9242-09173F13E4C5 n4:271B461B-363D-11E5-9242-09173F13E4C5 n4:271B461C-363D-11E5-9242-09173F13E4C5 n4:271B4619-363D-11E5-9242-09173F13E4C5 n4:271B461A-363D-11E5-9242-09173F13E4C5 n4:271B4617-363D-11E5-9242-09173F13E4C5 n4:271B4618-363D-11E5-9242-09173F13E4C5 n4:271B4615-363D-11E5-9242-09173F13E4C5 n4:271B4616-363D-11E5-9242-09173F13E4C5 n4:271B4613-363D-11E5-9242-09173F13E4C5 n4:271B4614-363D-11E5-9242-09173F13E4C5 n4:271B4611-363D-11E5-9242-09173F13E4C5 n4:271B4612-363D-11E5-9242-09173F13E4C5 n4:271B4610-363D-11E5-9242-09173F13E4C5
n3:synonym
Salsalatum Salicyloylsalicylic acid O-Salicylcylsalicylsaeure Sasapyrinum Salicylic acid bimolecular ester Sasapyrin salicylsalicylic acid Disalicylic acid 2-Carboxyphenyl salicylate O-Salicylsalicylic acid Salicyloxysalicylic acid Disalicylsaeure Salsalato Sasapyrine Disalcid
n3:toxicity
Death has followed ingestion of 10 to 30 g of salicylates in adults, but much larger amounts have been ingested without fatal outcome.
n3:proteinBinding
Salicylate: 90-95% bound at plasma salicylate concentrations <100 mcg/mL; 70-85% bound at concentrations of 100-400 mcg/mL; 25-60% bound at concentrations >400 mcg/mL.
n9:hasConcept
n10:M0062507
foaf:page
n12:salsalate.htm n22:salsalate.html n23:dis1142.shtml
n3:IUPAC-Name
n5:271B4630-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4636-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4635-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4632-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4633-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4634-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B462E-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B462F-363D-11E5-9242-09173F13E4C5 n5:271B462C-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B462D-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:N02BA06
n3:H-Bond-Acceptor-Count
n5:271B463C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B463D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4637-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4638-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B463A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4639-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B463B-363D-11E5-9242-09173F13E4C5
n3:absorption
Salsalate is insoluble in acid gastric fluids (< 0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged. The amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Food slows the absorption of all salicylates including salsalate.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
552-94-3
n3:category
n3:containedIn
n6:271B462B-363D-11E5-9242-09173F13E4C5 n6:271B4629-363D-11E5-9242-09173F13E4C5 n6:271B462A-363D-11E5-9242-09173F13E4C5 n6:271B4627-363D-11E5-9242-09173F13E4C5 n6:271B4628-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4642-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4644-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4645-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4646-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4641-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4640-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4643-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4631-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B463E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B463F-363D-11E5-9242-09173F13E4C5